High blood soluble receptor p80 for tumour necrosis factor‐α is associated with erythropoietin resistance in haemodialysis patients | Zendy

Atsushi Kato | Zendy; Mari Odamaki | Zendy; TOMOHISA TAKITA | Zendy; Mitsuyoshi Furuhashi | Zendy; Y Maruyama | Zendy; Akira Hishida | Zendy

Open Access

High blood soluble receptor p80 for tumour necrosis factor‐α is associated with erythropoietin resistance in haemodialysis patients

Author(s) -

Atsushi Kato,

Mari Odamaki,

TOMOHISA TAKITA,

Mitsuyoshi Furuhashi,

Y Maruyama,

Akira Hishida

Publication year - 2001

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/16.9.1838

Subject(s) - medicine , erythropoietin , hemodialysis , necrosis , tumor necrosis factor alpha , receptor , endocrinology

Inflammation is one of the major causes of resistance to erythropoietin (rHuEpo) treatment. Tumour necrosis factor-alpha (TNF-alpha), one of the most potent proinflammatory cytokines, is known to inhibit human erythropoiesis directly in vitro. Although blood levels of soluble receptors for TNF-alpha (sTNFRs) are elevated in haemodialysis (HD) patients, the role of sTNFR for rHuEpo responsiveness in HD patients remains to be clarified.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog